Astragaloside IV suppresses development of hepatocellular carcinoma by regulating miR-150-5p/β-catenin axis

Cui, Xiang; Jiang, Xiaoyan; Wei, Chunshan; Xing, Yufeng; Tong, Guangdong

doi:10.1016/j.etap.2020.103397

Cited by 28 publications

(20 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The dried root of this plant is called huang qi and an astragaloside IV (AS-IV) is the core bio-active ingredient of huang qi. Recently, it was reported that AS-IV showed anti-oxidative, anti-cancer, and hepato-protective activity in a variety of experiments [ 41 , 42 , 43 ]. Looking at recent research, it seems likely that AS-IV has many pharmacological potential.…”

Section: Discussionmentioning

confidence: 99%

Astragaloside IV Suppresses Hepatic Proliferation in Regenerating Rat Liver after 70% Partial Hepatectomy via Down-Regulation of Cell Cycle Pathway and DNA Replication

et al. 2021

View full text Add to dashboard Cite

Astragaloside IV (AS-IV) is one of the major bio-active ingredients of huang qi which is the dried root of Astragalus membranaceus (a traditional Chinese medicinal plant). The pharmacological effects of AS-IV, including anti-oxidative, anti-cancer, and anti-diabetic effects have been actively studied, however, the effects of AS-IV on liver regeneration have not yet been fully described. Thus, the aim of this study was to explore the effects of AS-IV on regenerating liver after 70% partial hepatectomy (PHx) in rats. Differentially expressed mRNAs, proliferative marker and growth factors were analyzed. AS-IV (10 mg/kg) was administrated orally 2 h before surgery. We found 20 core genes showed effects of AS-IV, many of which were involved with functions related to DNA replication during cell division. AS-IV down-regulates MAPK signaling, PI3/Akt signaling, and cell cycle pathway. Hepatocyte growth factor (HGF) and cyclin D1 expression were also decreased by AS-IV administration. Transforming growth factor β1 (TGFβ1, growth regulation signal) was slightly increased. In short, AS-IV down-regulated proliferative signals and genes related to DNA replication. In conclusion, AS-IV showed anti-proliferative activity in regenerating liver tissue after 70% PHx.

show abstract

Section: Discussionmentioning

confidence: 99%

Astragaloside IV Suppresses Hepatic Proliferation in Regenerating Rat Liver after 70% Partial Hepatectomy via Down-Regulation of Cell Cycle Pathway and DNA Replication

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, Bcl-2 can inhibit the release of cyt c and avoid the intrinsic apoptosis induced by Bax (15). Research has indicated that AS-IV can enhance the Bax/Bcl-2 ratio to induce intrinsic apoptosis in a number of types of cancer, including colorectal cancer (cRc), breast cancer, lung cancer, vulvar squamous cell cancer (VScc) and hepatocellular carcinoma (Hcc) (16)(17)(18)(19)(20)(21).…”

Section: Effects Of As-iv In Cancer Modelsmentioning

confidence: 99%

“…Similar to miR-134, miR-150-5p markedly downregulates β-catenin in liver carcinoma, functioning as an inhibitor to attenuate the proliferation of cancer cells. It has been well-established that AS-IV can regulate the miR150-5p/β-catenin axis to induce the apoptosis of Hcc cells (20).…”

Section: Inhibition Of Metastasis Matrix Metalloproteinases (Mmps)mentioning

confidence: 99%

Molecular mechanisms of astragaloside‑IV in cancer therapy (Review)

2021

View full text Add to dashboard Cite

“…Recent studies have reported that AS-IV can suppress kidney fibrosis and exert beneficial effects on diabetes and its related complications via multiple mechanisms (Wang E. et al, 2020). AS-IV is also known to function as a regulator of miRNAs levels (Gong et al, 2018;Cui et al, 2020). We therefore hypothesized that miR-98-5p might participate in the pathological process of Gd-IgA1 production and could be regulated by AS-IV in IgAN.…”

Section: Introductionmentioning

confidence: 99%

Astragaloside IV Inhibits Galactose-Deficient IgA1 Secretion via miR-98-5p in Pediatric IgA Nephropathy

Liu

Shuai

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Purpose: The factor associated with IgA nephropathy (IgAN) is an abnormality of IgA known as galactose-deficient IgA1 (Gd-IgA1). The purpose of this study was to determine the molecular role played by miRNAs in the formation of Gd-IgA1 in IgAN and investigate the regulatory role of Astragaloside IV (AS-IV) in miRNAs.Patients and methods: Bioinformatics analysis, along with functional and mechanistic experiments, were used to investigate the relationship and function of miRNA, β-1, 3-galactosyltransferase (C1GALT1), Gd-IgA1, and AS-IV. Analyses involved a series of tools, including quantitative real-time polymerase chain reaction (qRT-qPCR), Western blot, enzyme-linked immunosorbent assay (ELISA), Vicia Villosa lectin-binding assay (VVA), Cell counting kit-8 assay (CCK-8), and the dual-luciferase reporter assay.Results: miRNA screening and validation showed that miR-98-5p was significantly upregulated in the peripheral blood mononuclear cells (PBMCs) of pediatric patients with IgAN compared with patients diagnosed with mesangial proliferative glomerulonephritis (MsPGN) and immunoglobulin A vasculitis nephritis (IgAV-N), and healthy controls (p < 0.05). Experiments with the dual-luciferase reporter confirmed that miR-98-5p might target C1GALT1. The overexpression of miR-98-5p in DAKIKI cells decreased both the mRNA and protein levels of C1GALT1 and increased the levels of Gd-IgA1 levels; these effects were reversed by co-transfection with the C1GALT1 plasmid, and vice versa. In addition, AS-IV downregulated the levels of Gd-IgA1 level in DAKIKI cells by inhibiting miR-98-5p.Conclusions: Our results revealed that AS-IV could inhibit Gd-IgA1 secretion via miR-98-5p. Increased levels of miR-98-5p in pediatric IgAN patients might affect the glycosylation of IgA1 by targeting C1GALT1. In addition, our analyses suggest that the pathogenesis of IgAN may differ from that of IgAV-N. Collectively, these results provide significant insight into the pathogenesis of IgAN and identify a potential therapeutic target.

show abstract

Astragaloside IV suppresses development of hepatocellular carcinoma by regulating miR-150-5p/β-catenin axis

Cited by 28 publications

References 43 publications

Astragaloside IV Suppresses Hepatic Proliferation in Regenerating Rat Liver after 70% Partial Hepatectomy via Down-Regulation of Cell Cycle Pathway and DNA Replication

Astragaloside IV Suppresses Hepatic Proliferation in Regenerating Rat Liver after 70% Partial Hepatectomy via Down-Regulation of Cell Cycle Pathway and DNA Replication

Molecular mechanisms of astragaloside‑IV in cancer therapy (Review)

Astragaloside IV Inhibits Galactose-Deficient IgA1 Secretion via miR-98-5p in Pediatric IgA Nephropathy

Contact Info

Product

Resources

About